Liquid biopsies have been a priority topic for policy development by US FDA and the broader Obama administration. During the past year, FDA has kicked itself into high gear to provide test-makers with more insight into its thinking and, this summer, the agency approved the first liquid biopsy test.
Roche Diagnostics Corp.'s cobasEGRF Mutation Test v2, approved in June as companion diagnostic to the lung cancer drug Tarceva,...